TY - JOUR
T1 - Use of Ceftaroline Fosamil in Children
T2 - Review of Current Knowledge and its Application
AU - Yim, Juwon
AU - Molloy, Leah M.
AU - Newland, Jason G.
N1 - Publisher Copyright:
© 2016, The Author(s).
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Ceftaroline is a novel cephalosporin recently approved in children for treatment of acute bacterial skin and soft tissue infections and community-acquired bacterial pneumonia (CABP) caused by methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae and other susceptible bacteria. With a favorable tolerability profile and efficacy proven in pediatric patients and excellent in vitro activity against resistant Gram-positive and Gram-negative bacteria, ceftaroline may serve as a therapeutic option for polymicrobial infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and resistant Gram-positive infections that fail first-line antimicrobial agents. However, limited data are available on tolerability in neonates and infants younger than 2 months of age, and on pharmacokinetic characteristics in children with chronic medical conditions and those with invasive, complicated infections. In this review, the microbiological profile of ceftaroline, its mechanism of action, and pharmacokinetic profile will be presented. Additionally, clinical evidence for use in pediatric patients and proposed place in therapy is discussed.
AB - Ceftaroline is a novel cephalosporin recently approved in children for treatment of acute bacterial skin and soft tissue infections and community-acquired bacterial pneumonia (CABP) caused by methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae and other susceptible bacteria. With a favorable tolerability profile and efficacy proven in pediatric patients and excellent in vitro activity against resistant Gram-positive and Gram-negative bacteria, ceftaroline may serve as a therapeutic option for polymicrobial infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and resistant Gram-positive infections that fail first-line antimicrobial agents. However, limited data are available on tolerability in neonates and infants younger than 2 months of age, and on pharmacokinetic characteristics in children with chronic medical conditions and those with invasive, complicated infections. In this review, the microbiological profile of ceftaroline, its mechanism of action, and pharmacokinetic profile will be presented. Additionally, clinical evidence for use in pediatric patients and proposed place in therapy is discussed.
KW - Antibiotic resistance
KW - Ceftaroline fosamil
KW - Children
KW - Methicillin-resistant Staphylococcus aureus
KW - Streptococcus pneumoniae
UR - http://www.scopus.com/inward/record.url?scp=85014657174&partnerID=8YFLogxK
U2 - 10.1007/s40121-016-0144-8
DO - 10.1007/s40121-016-0144-8
M3 - Review article
C2 - 28039666
AN - SCOPUS:85014657174
SN - 2193-8229
VL - 6
SP - 57
EP - 67
JO - Infectious Diseases and Therapy
JF - Infectious Diseases and Therapy
IS - 1
ER -